Pharsight

Delstrigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

Delstrigo is owned by Msd Merck Co.

Delstrigo contains Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate.

Delstrigo has a total of 3 drug patents out of which 0 drug patents have expired.

Delstrigo was authorised for market use on 30 August, 2018.

Delstrigo is available in tablet;oral dosage forms.

Delstrigo can be used as treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to the individual components of delstrigo; for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed.

The generics of Delstrigo are possible to be released after 29 November, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to...

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage

DELSTRIGO family patents

Family Patents